Navigation Links
Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
Date:5/21/2009

nited States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer.(i) In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The Dimebon program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

(i) American Cancer Society

    Contacts:
    Medivation, Inc.                                WeissComm Partners
    Patrick Machado,
'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
11. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
(Date:10/25/2014)... 2014 (HealthDay News) -- Not getting the right amount ... a new study suggests. Those who sleep less ... per night may be more prone to developing the ... report. The study authors concluded that duration and quality ... patients with inflammatory bowel diseases. "Both short and ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
(Date:10/22/2014)... TX (PRWEB) October 22, 2014 On ... Criminal Minds featuring skin diseases both fictional and ... (CEHMDF), a nonprofit organization committed to advocacy and ... if CBS will take the opportunity to impart truth ... , There are many misconceptions about ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... Ebola cases in Dallas. But, mental health specialists say overblown ... President Barack Obama on Friday appointed an Ebola "czar" to ... two Dallas nurses who cared for a Liberian man who ... But the U.S. cases are miniscule in the context ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3
... A drug whose clinical benefit in treating multiple sclerosis was ... Food and Drug Administration on January 22 and is now ... is the first therapy for multiple sclerosis that can be ... to treat impaired walking, a debilitating symptom of the disease ...
... ... renewed its multi year relationship with Seventh Generation, the leading global brand of green ... paper towels. , ... Hong Kong, China (April 1, 2010) – Serendipity House Limited, Hong Kong’s leading provider ...
... ... a new survey of U.S. healthcare organizations suggests that while organizations are updating their ... ... the healthcare industry prepares for a major shift to electronic health records (EHRs) over ...
... ... Techniques Are Impacting the Face of the Senior Care Industry , ... Newport Beach, Calif. (PRWEB) April 5, ... on how elder care marketers grow their businesses. The Elder Care Marketing Industry Report, ...
... discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has ... of conflicting data concerning XMRV, standardized diagnostic testing is ... and to determine whether it plays a role in ... the April issue of Urology is a ...
... Research on antibodies may aid vaccine development , MONDAY, April ... insight into how the body fights off HIV, a finding ... the virus, which causes AIDS. , At the moment, there,s ... develop a vaccine. HIV remains an extremely stubborn enemy. , ...
Cached Medicine News:Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 2Health News:Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center 3Health News:Serendipity House Limited, the Leading Provider of Natural and Organic Products in Hong Kong, Renews Multi-year Relationship with Seventh Generation 2Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 2Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 3Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 4Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 5Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 6Health News:Healthcare Industry Continues to Overlook Critical Gaps in Data Security, According to New Bi-Annual Report 7Health News:New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population 2Health News:New Study on Elder Care Marketing Reveals Fresh Insights in Targeting Aging Population 3Health News:New investigation supports correlation between XMRV and prostate cancer 2Health News:Scientists Find Clues to How the Body Fights Off HIV 2
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... LA VERNE, Calif. , Oct. 22, 2014 ... emergency readiness products, has developed APLS ® ... bag that minimizes the spread of bacteria and ... APLS Body Guard Bio features a ... and finished edges that create a leak-proof inner ...
(Date:10/22/2014)... , Oct. 22, 2014  With a ... animal health medications, a Global Pharmaceutical and Biotech ... serialization technology and turnkey solution to protect their ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... that was serialized and aggregated by the Xyntek ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 31 United,Therapeutics Corporation (Nasdaq: UTHR ) ... that they will release the results of their,TRIUMPH-1 ... of treprostinil,in pulmonary arterial hypertension (PAH) before market ... will expand its previously scheduled conference,call on November ...
... WASHINGTON, Oct. 31 American Meat Institute,Foundation Vice ... a response to the World Cancer Research Fund ... be available at the National Press,Club following WCRF,s ... Institute (AMI) is the nation,s oldest and largest,association ...
Cached Medicine Technology:Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: